These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 29964008)

  • 1. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
    Zhang Q; Wang C; Han X; Yang G; Ge Z; Zhang G
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2333-2339. PubMed ID: 29964008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GOLPH3 inhibition reverses oxaliplatin resistance of colon cancer cells via suppression of PI3K/AKT/mTOR pathway.
    Yu T; An Q; Cao XL; Yang H; Cui J; Li ZJ; Xiao G
    Life Sci; 2020 Nov; 260():118294. PubMed ID: 32818544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpressed CES2 has prognostic value in CRC and knockdown CES2 reverses L-OHP-resistance in CRC cells by inhibition of the PI3K signaling pathway.
    Zhang Y; Sun L; Sun Y; Chen Y; Wang X; Xu M; Chi P; Xu Z; Lu X
    Exp Cell Res; 2020 Apr; 389(1):111856. PubMed ID: 31981591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knockdown of KLK11 reverses oxaliplatin resistance by inhibiting proliferation and activating apoptosis via suppressing the PI3K/AKT signal pathway in colorectal cancer cell.
    Zhang Y; Xu Z; Sun Y; Chi P; Lu X
    Onco Targets Ther; 2018; 11():809-821. PubMed ID: 29497313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [ADAM17 knockdown increases sensitivity of SW480 cells to cetuximad].
    Chen Y; Zheng K; Chen Z; Feng H; Fang W; Huang Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Nov; 38(11):1366-1371. PubMed ID: 30514687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway.
    Liu B; Liu Y; Zhao L; Pan Y; Shan Y; Li Y; Jia L
    Mol Carcinog; 2017 Dec; 56(12):2669-2680. PubMed ID: 28767179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway.
    Wang XJ; Feng CW; Li M
    Mol Cell Biochem; 2013 Aug; 380(1-2):57-66. PubMed ID: 23625205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of YEATS4 by miR-218 sensitizes colorectal cancer cells to L-OHP-induced cell apoptosis by inhibiting cytoprotective autophagy.
    Fu Q; Cheng J; Zhang J; Zhang Y; Chen X; Xie J; Luo S
    Oncol Rep; 2016 Dec; 36(6):3682-3690. PubMed ID: 27779719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-200b-3p mitigates oxaliplatin resistance via targeting TUBB3 in colorectal cancer.
    Wu YZ; Lin HY; Zhang Y; Chen WF
    J Gene Med; 2020 Jul; 22(7):e3178. PubMed ID: 32092782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway.
    Xu R; Zhang Y; Li A; Ma Y; Cai W; Song L; Xie Y; Zhou S; Cao W; Tang X
    Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33982772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GDF15 induces chemoresistance to oxaliplatin by forming a reciprocal feedback loop with Nrf2 to maintain redox homeostasis in colorectal cancer.
    Lin H; Luo Y; Gong T; Fang H; Li H; Ye G; Zhang Y; Zhong M
    Cell Oncol (Dordr); 2024 Aug; 47(4):1149-1165. PubMed ID: 38386232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S100A6 mediated epithelial-mesenchymal transition affects chemosensitivity of colorectal cancer to oxaliplatin.
    Zhang C; Zeng M; Xu Y; Huang B; Shi P; Zhu X; Cao Y
    Gene; 2024 Jul; 914():148406. PubMed ID: 38521111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of miR-19a partially reversed the resistance of colorectal cancer to oxaliplatin via PTEN/PI3K/AKT pathway.
    Zhang Y; Liu X; Zhang J; Xu Y; Shao J; Hu Y; Shu P; Cheng H
    Aging (Albany NY); 2020 Mar; 12(7):5640-5650. PubMed ID: 32209726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Anthraquinone Derivative C2 Enhances Oxaliplatin-Induced Cell Death and Triggers Autophagy via the PI3K/AKT/mTOR Pathway.
    Li Y; Yan W; Qin Y; Zhang L; Xiao S
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ADAM17-siRNA inhibits MCF-7 breast cancer through EGFR-PI3K-AKT activation.
    Meng X; Hu B; Hossain MM; Chen G; Sun Y; Zhang X
    Int J Oncol; 2016 Aug; 49(2):682-90. PubMed ID: 27221510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
    Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
    Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosmarinic acid inhibits proliferation and migration, promotes apoptosis and enhances cisplatin sensitivity of melanoma cells through inhibiting ADAM17/EGFR/AKT/GSK3β axis.
    Huang L; Chen J; Quan J; Xiang D
    Bioengineered; 2021 Dec; 12(1):3065-3076. PubMed ID: 34224305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypermethylated and downregulated MEIS2 are involved in stemness properties and oxaliplatin-based chemotherapy resistance of colorectal cancer.
    Wang X; Ghareeb WM; Zhang Y; Yu Q; Lu X; Huang Y; Huang S; Sun Y; Chi P
    J Cell Physiol; 2019 Aug; 234(10):18180-18191. PubMed ID: 30859572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATXN2L upregulated by epidermal growth factor promotes gastric cancer cell invasiveness and oxaliplatin resistance.
    Lin L; Li X; Pan C; Lin W; Shao R; Liu Y; Zhang J; Luo Y; Qian K; Shi M; Bin J; Liao Y; Liao W
    Cell Death Dis; 2019 Feb; 10(3):173. PubMed ID: 30787271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zuo Jin Wan reverses P-gp-mediated drug-resistance by inhibiting activation of the PI3K/Akt/NF-κB pathway.
    Sui H; Pan SF; Feng Y; Jin BH; Liu X; Zhou LH; Hou FG; Wang WH; Fu XL; Han ZF; Ren JL; Shi XL; Zhu HR; Li Q
    BMC Complement Altern Med; 2014 Aug; 14():279. PubMed ID: 25085593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.